Company intelligence / Profile preview
InnaVirVax
Evry, Île-de-France, Franceinnavirvax.fr ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Other
01
Overview
VAC‑3S, a therapeutic vaccine for HIV, has reached Phase IIa clinical development. The company’s approach targets the preservation of CD4+ T cells by modulating innate immunity. Preclinical studies have shown efficacy in non-human primates, and first-in-human studies have been authorized. Other pipeline assets include an AIDS prognostic test and an innovative cancer biotherapy.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- VaccineBiologicImmunotherapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
FIT Biotech Oy – collaboration to combine proprietary immunotherapies for a functional cure of HIV using both companies’ vaccine technologies.
Beyond the preview
Go deeper on InnaVirVax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InnaVirVax.